Bristol Myers Squibb (BMY)
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-11-05
$63.13-1.65%
Close 2026-11-05 · 1-day change
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-11-05
QuarterlyIQ Insights · BMY
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How this business ranks within health care on a research-validated quality screen. As of 2026-11-05.
The screen ranks BMY against its sector on four durable signals: share dilution, return on capital, free-cash-flow yield, and FCF margin. Historically the highest-quality names tended toward better typical outcomes and fewer bad years over multi-year holds (strongest at three years, modest at one), and that pattern showed up even before the price moved. It characterizes business quality, not price direction.
Each leg is a sector-relative percentile (higher is better); 3 of 4 legs were available for this name. The composite is built from these four; the raw value follows each percentile for context.
A forward quality tilt, not a price prediction, and context for your own research rather than a recommendation. Not investment advice.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 53% of the time over the next year (vs 42% for the rest of the cohort, n=10089).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
As we advance our multi-year strategy to position the company for long-term growth, we are guided by the following priorities: • Focusing R&D on high-impact, transformational medicines to treat life-…
Stated in 3 of 8 supplied quarters. Management reported: “This reflects an anticipated revenue decline for the Legacy Portfolio of approximately 12-16%.” “This is expected to be partially offset by the continued strength of our Growth Portfolio.” Revenue was $13.069 billion in 2026-Q3.
“As we advance our multi-year strategy to position the company for long-term growth, we are guided by the following priorities: • Focusing R&D on high-impact, transformational medicines to treat life-…”
“As we advance our multi-year strategy to position the company for long-term growth, we are guided by the following priorities: • Focusing R&D on high-impact, transformational medicines to treat life-…”
“As we advance our multi-year strategy to position the company for long-term growth, we are guided by the following priorities: • Focusing R&D on high-impact, transformational medicines to treat life-…”
• Research and development expenses of $2.6 billion decreased 19% on a GAAP basis and 8% on a non-GAAP basis, primarily driven by our ongoing strategic productivity initiative.
Stated in 3 of 8 supplied quarters. Management reported: “• Research and development expenses of $2.6 billion decreased 19% on a GAAP basis and 8% on a non-GAAP basis, primarily driven by our ongoing strategic productivity initiative.” “• Selling, general and administrative expenses of $7.3 billion decreased 14% on a GAAP basis and decreased 11% to $7.1 billion on a non-GAAP basis, primarily driven by our ongoing strategic productivity initiative.”
As we advance our multi-year strategy to position the company for long-term growth, we are guided by the following priorities: • Focusing R&D on high-impact, transformational medicines to treat life-…
Stated in 3 of 8 supplied quarters. Management reported: “This is the 17 th consecutive year the company has increased its dividend and the 94 th consecutive year it has paid a dividend.” “Subject to normal quarterly review by the Board, the annual dividend rate for fiscal year 2026 is $2.52 per share.”
As we advance our multi-year strategy to position the company for long-term growth, we are guided by the following priorities: • Focusing R&D on high-impact, transformational medicines to treat life-…
Stated in 3 of 8 supplied quarters. Management reported: “"2026 is data-rich, and we are advancing a truly differentiated pipeline with multiple pivotal readouts expected in the back half of the year.” “7 Business Development In January 2026, the company announced an agreement with Microsoft aimed at accelerating early detection of lung cancer.”
Update the 2026 full-year outlook as portfolio momentum develops, including revenue and non-GAAP EPS ranges.
Over the trailing year it converted -2.02x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity (low R² over the window).
3 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 43% of the time over the next year (vs 45% for the rest of the cohort, n=9530).
Not investment advice. As of 2026-11-05.
“• Research and development expenses of $2.6 billion decreased 19% on a GAAP basis and 8% on a non-GAAP basis, primarily driven by our ongoing strategic productivity initiative.”
“• Selling, general and administrative expenses of $1.7 billion decreased 11% on a GAAP basis and 12% on a non-GAAP basis, primarily driven by our ongoing strategic productivity initiative.”
“Update on Strategic Productivity Initiative Bristol Myers Squibb is expanding its existing strategic productivity initiative to include approximately $2 billion in additional annualized cost savings…”
“As we advance our multi-year strategy to position the company for long-term growth, we are guided by the following priorities: • Focusing R&D on high-impact, transformational medicines to treat life-…”
“As we advance our multi-year strategy to position the company for long-term growth, we are guided by the following priorities: • Focusing R&D on high-impact, transformational medicines to treat life-…”
“As we advance our multi-year strategy to position the company for long-term growth, we are guided by the following priorities: • Focusing R&D on high-impact, transformational medicines to treat life-…”
“As we advance our multi-year strategy to position the company for long-term growth, we are guided by the following priorities: • Focusing R&D on high-impact, transformational medicines to treat life-…”
“As we advance our multi-year strategy to position the company for long-term growth, we are guided by the following priorities: • Focusing R&D on high-impact, transformational medicines to treat life-…”
“As we advance our multi-year strategy to position the company for long-term growth, we are guided by the following priorities: • Focusing R&D on high-impact, transformational medicines to treat life-…”